Gilead opts in at long last, and that’s more than many might have been expecting.
Followers of novel immuno-oncology mechanisms will note Astrazeneca as a new player in Tigit and Tim3.
Data are due in the fourth quarter for Aldeyra, Aeglea and Radius, among other small developers.
As data non-disclosure prompts sellside guesswork one indisputable fact stands out: Gilead has not opted in to Arcus’s domvanalimab.
The anti-Tigit MAb domvanalimab will generate key clinical results any day; will they be good enough for Gilead to opt in?
Next week’s virtual meeting could resuscitate Ox40 agonists, but an important omission will disappoint.